Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% - Ars Technica

Fecha de publicación: 22 de octubre de 2026, 22:12

Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% Ars Technica Moderna’s Stock Plummets After Cancer-Vaccine Data Shared on Social Media WSJ ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows The Guardian Moderna shares…